Viral infection after renal transplantation: Surveillance and management

被引:97
作者
Weikert, Blair C. [1 ]
Blumberg, Emily A. [1 ]
机构
[1] Hosp Univ Penn, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2008年 / 3卷
关键词
D O I
10.2215/CJN.02900707
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Viral infections remain a significant cause of morbidity and mortality following renal transplantation. Although cytomegalovirus is the most common opportunistic pathogen seen in transplant recipients, numerous other viruses have also affected outcomes. In some cases, preventive measures such as pretransplant screening, prophylactic antiviral therapy, or post transplant viral monitoring may limit the impact of these infections. Recent advances in laboratory monitoring and antiviral therapy have improved outcomes. This review will summarize the major viral infections seen following transplant and discuss strategies for prevention and management of these potential pathogens.
引用
收藏
页码:S76 / S86
页数:11
相关论文
共 106 条
[1]   The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients [J].
Abbott, KC ;
Lentine, KL ;
Bucci, JR ;
Agodoa, LY ;
Peters, TG ;
Schnitzler, MA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (12) :2032-2037
[2]   Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression [J].
Abbott, KC ;
Swanson, SJ ;
Agodoa, LYC ;
Kimmel, PL .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06) :1633-1639
[3]   Late-onset acute haemorrhagic necrotizing granulomatous adenovirus tubulointerstitial nephritis in a renal allograft [J].
Alsaad, Khaled O. ;
Tobar, Ana ;
Belanger, Eric ;
Ahmad, Mufazzal ;
Cattran, Daniel C. ;
Herzenberg, Andrew M. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (04) :1257-1260
[4]  
[Anonymous], 2004, AM J TRANSPLANT, V4, P160
[5]   Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].
Asberg, A. ;
Humar, A. ;
Rollag, H. ;
Jardine, A. G. ;
Mouas, H. ;
Pescovitz, M. D. ;
Sgarabotto, D. ;
Tuncer, M. ;
Noronha, I. L. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113
[6]   Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: A single center experience [J].
Babel, N ;
Gabdrakhmanova, L ;
Juergensen, JS ;
Eibl, N ;
Hoerstrup, J ;
Hammer, M ;
Rosenberger, C ;
Hoeflich, C ;
Frei, U ;
Rohde, F ;
Volk, HD ;
Reinke, P .
TRANSPLANTATION, 2004, 78 (02) :283-285
[7]  
Birk PE, 1997, J AM SOC NEPHROL, V8, P1801
[8]   Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients [J].
Boivin, G ;
Goyette, N ;
Gilbert, C ;
Roberts, N ;
Macey, K ;
Paya, C ;
Pescovitz, MD ;
Humar, A ;
Dominguez, E ;
Washburn, K ;
Blumberg, E ;
Alexander, B ;
Freeman, R ;
Heaton, N ;
Covington, E .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) :1615-1618
[9]  
Boubenider S, 1999, J NEPHROL, V12, P24
[10]  
Brennan DC, 2001, J AM SOC NEPHROL, V12, P848, DOI 10.1681/ASN.V124848